Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Turns Back To Virology With $1.4bn MYR Acquisition

Executive Summary

MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.

You may also be interested in...



Eiger Expects To Join Gilead In Future Multi-Billion Dollar Hepatitis D Market

The little-known company could be set for a transformational year, with a Phase III readout in hepatitis D and a filing for a promising COVID-19 candidate.

Keeping Track: A Lawsuit-Driven Complete Response Letter, A Refuse To File Letter, And Some Good News

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes

Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC143472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel